Jointly outline a new blueprint for growth! Keyuan Pharma & Linuo Pharma appeared at the 18th Growth Pharmaceutical Enterprise Development Conference!
Recently, the highly anticipated 18th Growth Pharmaceutical Enterprise Development Conference was grandly held at the Xiamen Baixiang Convention and Exhibition Center. The conference was themed "Growth Power-Common Challenges and Responsibilities" and brought together many leading domestic pharmaceutical companies, experts and scholars, investment institutions and other elites to explor the future development path of the pharmaceutical industry with responsibility as the foundation and challenges as the wings. Keyuan Pharma (stock code: 301281.SZ) & Linuo Pharma appeared at this conference and won many awards from the conference.
In the exploration of the growth power of pharmaceutical companies, "common challenges and responsibilities" have become keywords that we cannot ignore. Faced with the rapidly changing market environment, increasingly stringent regulatory requirements and escalating consumer demand, pharmaceutical companies need to work together to jointly cope with challenges in product quality, technological innovation, cost control and social responsibility.
Facing the challenges and responsibilities of growth, Keyuan Pharma & Linuo Pharma have demonstrated outstanding efforts and responsibilities. Keyuan Pharma & Linuo Pharma take technology R&D, digital intelligence manufacturing, and cultural marketing as main driving forces, invests a lot of resources to promote product upgrades, builds provincial enterprise technology centers, Jinan municipal postdoctoral innovation practice bases, etc., and has established long-term and stable cooperative relationships with many R&D companies and universities to jointly carry out scientific and technological project research, scientific and technological achievement transformation, and scientific and technological talent training to achieve steady development of enterprises.
Keyuan Pharma actively builds a high-end intelligent manufacturing factory that integrates digitalization and informatization with the latest technology design, forming a safe, green, low-carbon, and environmentally friendly smart industrial park, making positive contributions to sustainable development and practicing corporate social responsibility with practical actions.
At the conference, Keyuan Pharma & Linuo Pharma had in-depth exchanges with the guests and actively participated in various theme activities, including "Capital helps industry reconstruction and renewal", "Under the background of slow speed, the new direction and path exploration of the integration of industry and capital of pharmaceutical and health enterprises" and "Grassroots medical development conference", etc., deeply analyzed the development trend of the pharmaceutical industry and shared successful experiences. Mr. Jiang Hongsheng, Chairman and President of Keyuan Pharma, served as the host of this capital sub-forum, leading the guests to discuss in depth the new model of capital and industry integration, and provided valuable ideas and suggestions for the transformation and upgrading of pharmaceutical and health enterprises.
With outstanding leadership and influence on the industry, Mr. Jiang Hongsheng won the honorary award of "Influential Entrepreneur of the Year" at the conference. Linuo Pharma won the "Annual Outstanding Brand Award" for outstanding performance in brand building, market expansion, quality assurance and other aspects.
Honor is not only a high recognition of strength, but also an effective incentive for future development. Keyuan Pharma & Lino Pharmaceutical will actively face the challenges and opportunities of growth with a more open attitude, innovative thinking and pragmatic actions, work together with upstream and downstream partners in the industrial chain to enhance the core competitiveness of the industry, continuously stimulate the innovative vitality and endogenous driving force of the pharmaceutical and health industry, and make new and greater contributions to building a digital health ecosystem and fully serving the Healthy China strategy.
